David Drew, MD
Hematology & Oncology · Fort Lauderdale, FLNPI 1407180615
Payments from drug & device makers
Across 449 payments — averaging $3400.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1M
- Genentech, Inc.$149K
- EMD Serono, Inc.$93K
- F. Hoffmann-la Roche AG$83K
- E.r. Squibb & Sons, L.L.C.$57K
- Otsuka Pharmaceutical Co., Ltd.$36K
- plus $62K from 34 others
What the payments were for
- Consulting fees$3,20040%
- Travel & lodging$80510%
- Food & beverage$3,36542%
- Education$6108%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 64 | $1,047,533 |
| Genentech, Inc. | 50 | $149,110 |
| EMD Serono, Inc. | 74 | $92,531 |
| F. Hoffmann-la Roche AG | 38 | $82,647 |
| E.r. Squibb & Sons, L.L.C. | 6 | $57,073 |
| Otsuka Pharmaceutical Co., Ltd. | 14 | $36,205 |
| Bristol Myers Squibb | 15 | $28,372 |
| Merck Healthcare Kgaa | 6 | $20,664 |
| Amgen | 11 | $4,342 |
| Janssen Research & Development, LLC | 10 | $4,240 |
| Organon | 1 | $520 |
| Astellas Pharma US Inc | 10 | $449 |
| Novartis | 22 | $442 |
| Johnson & Johnson(2 entities) | 17 | $353 |
| Pfizer | 29 | $334 |
| AstraZeneca | 10 | $328 |
| Genentech USA, Inc. | 17 | $309 |
| AbbVie | 13 | $268 |
| Abbott | 1 | $144 |
| Dova Pharmaceuticals | 5 | $69 |
| Boston Scientific | 3 | $66 |
| Seagen Inc. | 3 | $65 |
| Lilly USA, LLC | 4 | $62 |
| Sanofi | 3 | $56 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Eisai Inc. | 2 | $45 |
| Alnylam Pharmaceuticals Inc. | 2 | $42 |
| Beigene USA, Inc. | 1 | $41 |
| Advanced Accelerator Applications | 3 | $38 |
| Ipsen Biopharmaceuticals, Inc | 2 | $35 |
| Tersera Therapeutics LLC | 1 | $29 |
| Tolmar, Inc. | 1 | $24 |
| Immunogen, Inc. | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Sobi, Inc | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Janssen Scientific Affairs, LLC | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$144
- TAGRISSO$115
How this compares
$1,526,630 in reported general payments places this provider in the 85th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 85 | $1,512,184 |
| TagrissoOsimertinib Mesylate | 35 | $611,438 |
| CabometyxCabozantinib S-Malate | 13 | $338,329 |
| PromactaEltrombopag Olamine | 25 | $319,473 |
| RevlimidLenalidomide | 14 | $314,846 |
| Lenalidomide | 17 | $262,613 |
| InlytaAxitinib | 12 | $251,475 |
| VenclextaVenetoclax | 13 | $187,885 |
| EliquisApixaban | 176 | $135,380 |
| Abiraterone Acetate | 43 | $109,640 |
| XareltoRivaroxaban | 39 | $48,565 |
| Imatinib Mesylate | 22 | $36,625 |
| Danazol | 31 | $10,391 |
| RetacritEpoetin Alfa-Epbx | 11 | $9,237 |
| Sucralfate | 23 | $2,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $328 | $611,43835 claims |
| PfizerInlyta, Eliquis, Retacrit | $334 | $396,092199 claims |
| NovartisPromacta | $442 | $319,47325 claims |
| Bristol Myers SquibbRevlimid | $28,372 | $314,84614 claims |
| AbbVieVenclexta | $268 | $187,88513 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $12 | $109,64043 claims |
| Johnson & JohnsonXarelto | $353 | $48,56539 claims |
| Lilly USA, LLCOlanzapine | $62 | $27719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Fort Lauderdale
- Edgardo SantosFort Lauderdale$2.3M
- Georges AzziFort Lauderdale$2.2M
- Carl LandgrenMiami$47.8M
- Julio ChavezTampa$16.4M
- Steven AttiaJacksonville$13.9M
- Santosh NairOrange City$13.5M
- Frederick LockeTampa$12.8M
- Tarek MekhailOrlando$11.2M
- Carlos AlemanyOrlando$10.9M
- Thomas GeorgeGainesville$10.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.